BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35104796)

  • 1. Association of mutations in DNA polymerase epsilon with increased CD8+ cell infiltration and prolonged progression-free survival in patients with meningiomas.
    Rutland JW; Dullea JT; Gill CM; Chaluts D; Ranti D; Ellis E; Arrighi-Allisan A; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Umphlett M; Shrivastava RK
    Neurosurg Focus; 2022 Feb; 52(2):E7. PubMed ID: 35104796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
    Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
    Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M
    Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.
    Chaluts D; Dullea JT; Ali M; Vasan V; Devarajan A; Rutland JW; Gill CM; Ellis E; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5165-5172. PubMed ID: 36348021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
    Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
    Vasan V; Dullea JT; Devarajan A; Ali M; Rutland JW; Gill CM; Kinoshita Y; McBride RB; Gliedman P; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
    J Neurooncol; 2023 Jan; 161(2):309-316. PubMed ID: 36436149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High polymerase ε expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer.
    Min KW; Kim WS; Kim DH; Son BK; Oh YH; Kwon MJ; Lee HS; Lee SE; Kim IA; Moon JY; Kim KY; Park JH
    PLoS One; 2020; 15(5):e0233066. PubMed ID: 32433714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
    He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
    Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
    Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
    Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas.
    Rapp C; Dettling S; Liu F; Ull AT; Warta R; Jungk C; Roesch S; Mock A; Sahm F; Schmidt M; Jungwirth G; Zweckberger K; Lamszus K; Gousias K; Kessler AF; Grabe N; Loehr M; Ketter R; Urbschat S; Senft C; Westphal M; Abdollahi A; Debus J; von Deimling A; Unterberg A; Simon M; Herold-Mende CC
    Clin Cancer Res; 2019 Sep; 25(17):5260-5270. PubMed ID: 31227506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
    Li Y; Bian Y; Wang K; Wan XP
    BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.